The Technical Analyst
Frequency Therapeutics [FREQ]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Frequency Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
4.76% $0.300
America/New_York / 3 nov 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 10.94 mill |
| EPS: | -1.900 |
| P/E: | -0.158 |
| Earnings Date: | Nov 01, 2023 |
| SharesOutstanding: | 36.52 mill |
| Avg Daily Volume: | 0.135 mill |
| RATING 2023-11-03 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.158 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -0.158 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.249 - 0.351 ( +/- 17.02%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-27 | Meyers Rachel | Buy | 12 551 | Stock Option (Right to Buy) |
| 2023-11-27 | Meyers Rachel | Buy | 0 | |
| 2023-11-22 | Lucchino David L. | Sell | 110 | Common Stock |
| 2023-11-22 | Lucchino David L. | Sell | 230 | Common Stock |
| 2023-11-22 | Lucchino David L. | Sell | 614 | Common Stock |
| INSIDER POWER |
|---|
| 96.43 |
| Last 81 transactions |
| Buy: 3 077 272 | Sell: 64 406 |
Forecast:
01:40 - $0.323
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.300 (4.76% ) |
| Volume | 0.309 mill |
| Avg. Vol. | 0.135 mill |
| % of Avg. Vol | 228.88 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FREQ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
FREQ
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Latest Press Releases
2023-11-03 15:31:00 - Press Release
Update: Korro Bio And Frequency Therapeutics Announce Closing Of Merger And Private Placement Of $117 Million
Cambridge, mass. and lexington, mass., nov. 03, 2023 (globe newswire) -- korro bio, inc. (korro) (nasdaq: krro), a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing rna, enabling treatment of both rare and highly prevalent diseases, today announced the completion of the previously announced business combination between frequency therapeutics, inc. (frequency; nasdaq: freq) and the entity formerly known as korro bio, inc. (korro bio). the combined company will operate under the name korro bio, inc., and its shares are expected to begin trading on the nasdaq capital market under the ticker symbol “krro” on november 6, 2023.
2023-11-03 12:19:00 - Press Release
Korro Bio And Frequency Therapeutics Announce Closing Of Merger And Private Placement Of $117 Million
Cambridge, mass. and lexington, mass., nov. 03, 2023 (globe newswire) -- korro bio, inc. (korro) (nasdaq: krro), a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing rna, enabling treatment of both rare and highly prevalent diseases, today announced the completion of the previously announced business combination between frequency therapeutics, inc. (frequency; nasdaq: freq) and the entity formerly known as korro bio, inc. (korro bio). the combined company will operate under the name korro bio, inc., and its shares are expected to begin trading on the nasdaq capital market under the ticker symbol “krro” on november 6, 2023.
2023-10-06 14:14:00 - Press Release
Frequency Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Frequency Therapeutics, Inc. - Freq
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of frequency therapeutics, inc. (nasdaqgs: freq) to korro bio, inc. under the terms of the proposed transaction, pre-merger frequency therapeutics stockholders are expected to own approximately 8% of the combined company. ksf is seeking to determine whether this consideration and the process that led to it are ad.
2023-08-10 16:01:00 - Press Release
Frequency Therapeutics Provides Business Updates And Second Quarter 2023 Financial Results
Lexington, mass.--(business wire)--frequency therapeutics, inc. (nasdaq: freq) today announced business updates and financial results for the second quarter ended june 30, 2023. in july, the company announced that it entered into a definitive merger agreement with korro bio, inc., a leading rna editing company focused on the discovery and development of novel genetic medicines. after the anticipated consummation of the merger, the combined company will operate under korro bio, inc. with a focus.
2023-07-21 10:53:00 - Press Release
Frequency Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Frequency Therapeutics, Inc. - Freq
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of frequency therapeutics, inc. (nasdaqgs: freq) to korro bio, inc. under the terms of the proposed transaction, pre-merger frequency therapeutics stockholders are expected to own approximately 8% of the combined company. ksf is seeking to determine whether this consideration and the process that led to it are ad.
Latest News
2023-07-17 13:32:37 - Zacks Investment Research
Frequency (FREQ) Up 77% on Merger Deal With Korro Bio
Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs. This combined entity is set to operate under the name Korro Bio, which will apply to trade on the NASDAQ under the ticker symbol KRRO.
2023-07-14 08:00:00 - InvestorPlace
Why Is Frequency Therapeutics (FREQ) Stock Up 44% Today?
Frequency Therapeutics (NASDAQ: FREQ ) stock is rocketing higher on Friday following news that it will combine with Korro Bio . This merger plan is designed to bring Korro Bio public and will focus on the development of its RNA editing programs.
2023-02-27 07:30:00 - Business Wire
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced that interim Chief Executive Officer and Chief Scientific Officer Christopher Loose, Ph.D., will present at the following March healthcare investor conferences: 43rd Annual Cowen Healthcare Conference: Dr. Loose will participate on a panel discussion on March 8th at 12:50 p.
2023-02-13 17:00:49 - Pulse2
FREQ Stock: 80.54% Plummet Explanation
The stock price of Frequency Therapeutics Inc (NASDAQ: FREQ) plummeted 80.54% in the most recent trading session. This is why.
2022-05-25 13:03:07 - Zacks Investment Research
Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock?
Frequency Therapeutics, Inc. (FREQ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-05-10 08:00:00 - PennyStocks
What to Know About Buying Penny Stocks on May 10th
Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 10th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-22 07:30:00 - Business Wire
Frequency Therapeutics to Participate in B. Riley Securities' Neuro & Ophthalmology Investor Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose and Vice President of Discovery Biology Dr. Sanjay Magavi will participate in a fireside presentation at the B. Riley Securities' Neuro & Ophthalmology Conference on April 28, 2022 at 3:30 pm
2022-04-18 17:05:40 - PennyStocks
Best Penny Stocks to Buy in 2022? 3 to Watch in Late April
Why these penny stocks could be worth watching as April ends The post Best Penny Stocks to Buy in 2022? 3 to Watch in Late April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-02-28 07:30:00 - Business Wire
Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that Chief Executive Officer David L. Lucchino will participate in two upcoming investor conferences: Cowen 42nd Annual Health Care Conference: Corporate Panel Discussion - Auditory and Ophthalmology, March 7, 2022, 2:10 p.m. to 3:10 p.m. EST Oppe
2021-12-09 13:18:09 - Benzinga
Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise
Frequency Therapeutics Inc (NASDAQ: FREQ) shared the results from its FX-322-113 study of FX-322 in severe sensorineural hearing loss (SNHL). The Phase 1b study, FX-322, was associated with a hearing signal, as shown by improvements by four subjects in a sentence-in-noise test.